Piramal Pharma announces growth of API manufacturing facilities

To serve its European biotech customers better, PPS will add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK facilityFor everyone its European biotech customers better, PPS will prove to add early development abilities both in, drug substance and drug product, from its Morpeth, United kingdom facility

Piramal Pharma Solutions (PPS), an agreement development and manufacturing organisation (CDMO) announced investments of USD 55 million across its sites in The United States and Asia to grow its API manufacturing abilities and capacities.

Part of USD 55 million investment goes into new multi-purpose plants, with more than 270kL of total capacity, to aid the present pipeline of roughly 80 late-stage programs that PPS is presently assisting its partners with at various global sites, a business statement stated.

PPS may also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development abilities from Ennore in India through additions of GMP kilo labs along with a pilot plant.

For everyone its European biotech customers better, PPS will prove to add early development abilities both in, drug substance and drug product, from its Morpeth, United kingdom facility, it stated.

The organization, a part of Piramal Enterprises Limited. (PEL), may also expand support functions for example analytical abilities, R&D infrastructure, automation also it systems whatsoever API sites through this investment.

“Using these investments, we are able to now offer the commercialisation in our pipeline well over 80 programs which are at Phase II or beyond, while allowing us additional convenience of future partnerships, PPS Chief executive officer Vivek Sharma stated.

Leave a Reply

Your email address will not be published. Required fields are marked *